The outbreak of the novel coronavirus in Wuhan, China, saw infection cases spread throughout the Asia-Pacific region. By April 13, 2024, India had faced over 45 million coronavirus cases. South Korea followed behind India as having had the second highest number of coronavirus cases in the Asia-Pacific region, with about 34.6 million cases. At the same time, Japan had almost 34 million cases. At the beginning of the outbreak, people in South Korea had been optimistic and predicted that the number of cases would start to stabilize. What is SARS CoV 2?Novel coronavirus, officially known as SARS CoV 2, is a disease which causes respiratory problems which can lead to difficulty breathing and pneumonia. The illness is similar to that of SARS which spread throughout China in 2003. After the outbreak of the coronavirus, various businesses and shops closed to prevent further spread of the disease. Impacts from flight cancellations and travel plans were felt across the Asia-Pacific region. Many people expressed feelings of anxiety as to how the virus would progress. Impact throughout Asia-PacificThe Coronavirus and its variants have affected the Asia-Pacific region in various ways. Out of all Asia-Pacific countries, India was highly affected by the pandemic and experienced more than 50 thousand deaths. However, the country also saw the highest number of recoveries within the APAC region, followed by South Korea and Japan.

This dataset provides values for CORONAVIRUS CASES reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

As of April 13, 2024, India had the highest number of confirmed deaths due to the outbreak of the novel coronavirus in the Asia-Pacific region, with over 533 thousand deaths. Comparatively, Indonesia, which had the second highest number of coronavirus deaths in the Asia-Pacific region, recorded approximately 162 thousand COVID-19 related deaths as of April 13, 2024. Contrastingly, Bhutan had reported 21 deaths due to COVID-19 as of April 13, 2024.

As of December 12, 2022, Hong Kong had the highest rate of coronavirus (COVID-19) cases reported in the previous seven days in the Asia-Pacific region, around 1.19 thousand cases per 100 thousand people. South Korea followed with 825 cases per 100,000 people in the past seven days.

As of November 18, 2022, the number of confirmed COVID-19 cases in Africa amounted to around 12.7 million, which represented around two percent of the infections around the world. By the same date, coronavirus cases globally were over 640 million, deaths were over six million, while approximately 620 million people recovered from the disease. On the African continent, South Africa was the most drastically affected country, with more than 3.6 million infections.

The African continent fighting the pandemic  

The African continent first came in contact with the coronavirus pandemic on February 14, 2020, in the northernmost part, particularly Egypt. Since then, the different governments took severe restrictive measures to try to curb the spread of the disease. Moreover, the official numbers of the African continent are significantly lower than those of Europe, North America, South America, and Asia. Nevertheless, the infectious disease still managed to have its effects on several countries. South Africa had the highest number of deaths. Morocco and Tunisia, the second and third most affected in Africa, recorded 16,002 and 27,824 deaths, respectively, while Egypt registered at 24,132 as of March 02, 2022.

The light at the end of the tunnel  

Although the African countries still have a long way to fully combat the virus, vaccination programs have been rolled out in the majority of Africa. Also, according to a survey, public opinion in several African countries shows a high willingness to be vaccinated, with Ethiopia having numbers as high as 94 percent. As of March 2022, Egypt was the country administering the highest number of vaccine doses, however, Seychelles had the highest per rate per 100 people .

Background: When a new pathogen emerges, consistent case reporting is critical for public health surveillance. Tracking cases geographically and over time is key for understanding the spread of an infectious disease and effectively designing interventions to contain and mitigate an epidemic. In this paper we describe the reporting systems on COVID-19 in Southeast Asia during the first wave in 2020, and highlight the impact of specific reporting methods.Methods: We reviewed key epidemiological variables from various sources including a regionally comprehensive dataset, national trackers, dashboards, and case bulletins for 11 countries during the first wave of the epidemic in Southeast Asia. We recorded timelines of shifts in epidemiological reporting systems and described the differences in how epidemiological data are reported across countries and timepoints.Results: Our findings suggest that countries in Southeast Asia generally reported precise and detailed epidemiological data during the first wave of the pandemic. Changes in reporting rarely occurred for demographic data, while reporting shifts for geographic and temporal data were frequent. Most countries provided COVID-19 individual-level data daily using HTML and PDF, necessitating scraping and extraction before data could be used in analyses.Conclusion: Our study highlights the importance of more nuanced analyses of COVID-19 epidemiological data within and across countries because of the frequent shifts in reporting. As governments continue to respond to impacts on health and the economy, data sharing also needs to be prioritised given its foundational role in policymaking, and in the implementation and evaluation of interventions.

As of April 13, 2024, South Korea had the highest number of coronavirus recoveries among the selected economies in the Asia-Pacific region, with about 34.5 million recoveries. Australia had the second highest number of coronavirus recoveries among the economies with available data in the Asia-Pacific region, with over 11.8 million recoveries as of April 13, 2024.

The global COVID-19 Diagnosis market was valued at USD 25.6 billion in 2025 and is expected to expand at a CAGR of 5.4% from 2025 to 2033, reaching USD 39.8 billion by 2033. The market growth is primarily driven by the increasing prevalence of COVID-19 infections, the introduction of advanced diagnostic technologies, and the growing need for accurate and timely diagnosis. Additionally, government initiatives and funding for COVID-19 research and development are further contributing to market expansion. Regional analysis reveals that North America held the largest market share in 2025, followed by Europe and Asia Pacific. The high prevalence of COVID-19 cases, well-established healthcare infrastructure, and access to advanced diagnostic technologies in these regions are key growth factors. Asia Pacific is expected to witness significant growth over the forecast period, owing to the increasing population, rising healthcare expenditure, and growing awareness of COVID-19 diagnosis. Key players in the market include Cepheid, Abbott, Mesa Biotech, Microsens Dx, GenMark Diagnostics, Credo, Quest Diagnostics, LabCorp, Roche Diagnostics, Thermo Fisher Scientific, BD, PerkinElmer, Quidel, and Abbott. These companies are focusing on developing innovative diagnostic technologies, expanding their geographic reach, and collaborating with healthcare providers to strengthen their market position.

Here we investigated whether the dengue fever pandemic of 2019-2020 may have influenced COVID-19 incidence and spread around the world. In Brazil, the geographic distribution of dengue fever was highly complementary to that of COVID-19. This was accompanied by an inverse correlation between COVID-19 and dengue fever incidence that could not be explained by socioeconomic factors. This inverse correlation was observed for 5,016 Brazilian municipalities reporting COVID-19 cases, 558 micro- and 137 meso-regions, 27 states and 5 regions. Brazilian states with high population levels of dengue IgM in 2020 exhibited: (i) lower COVID-19 case and death incidence, (ii) slower infection growth rates, and (iii) took longer to accumulate COVID-19 cases. No such inverse correlations were observed for the chikungunya virus, which is also transmitted by the Aedes aegypti mosquito. The same inverse correlation between COVID-19 and dengue fever incidence was observed for 145 locations (66 countries and the 64 states of Mexico and Colombia) in Latin America, the Caribbean, and Asia. Countries with high dengue incidence took longer to accumulate COVID-19 cases than those without dengue. Although the dataset considered has quality and availability limitations, these findings raise the possibility of an immunological cross-reaction between dengue virus serotypes and SARS-CoV-2, which could have led to partial immunological protection for COVID-19 in dengue infected communities. However, further studies are necessary to better test this hypothesis.

The COVID-19 outbreak at the beginning of 2020 has drastically impacted almost every aspect of our daily life. Empirical evidence is lacking on which sector of knowledge in technology-enhanced teaching needs to be developed further for tourism and hospitality programs conducted online. The present study investigated teachers’ technology, learners, pedagogy, academic discipline content knowledge, and context knowledge (TLPACK) in tourism and hospitality online education settings using comparative research methods. A total of 173 participants from five countries (Indonesia, Philippines, Taiwan, Thailand, and Vietnam) were surveyed online. The results revealed that, despite the fact that they were from different countries, all teachers reached a consensus that their knowledge about learners was the lowest during the online teaching period of the pandemic; meanwhile, they all ranked academic knowledge as the highest among these five variables except Vietnamese teachers who considered their knowledge on pedagogy to be the highest. Additionally, their TLPACK revealed significant differences in various countries and differences in academic discipline content knowledge are caused by the interaction of nationality and gender. This study overcomes a major limitation of previous studies on how the pandemic has affected educational praxis as the focus of previous research has been on the situation in a single country. Therefore, the present study’s findings can serve as a reference for practitioners of tourism and hospitality online education in Asia-Pacific region when facing unprecedented and urgent changes of educational practices during and post the COVID-19 pandemic.

The global chloroquine drug market for COVID-19 is projected to be valued at USD 0.87 billion in 2025 and is expected to expand at a CAGR of 12.9% during the forecast period, reaching USD 1.96 billion by 2033. The rapid spread of the COVID-19 virus, coupled with the increasing demand for effective treatment options, is driving the market growth. Chloroquine has shown early promise in treating COVID-19 symptoms by inhibiting the virus's replication. The market is expected to continue expanding as governments worldwide invest in research and development of effective treatments for COVID-19. The market is segmented into applications (mild symptom patients, critically ill patients), types (tablets, injections), and regions (North America, Europe, Asia Pacific, Middle East & Africa, South America). The tablet segment held the largest market share in 2025, accounting for over 65% of the global market. However, the injection segment is expected to grow at a faster rate during the forecast period due to the increasing preference for intravenous administration in critically ill patients. North America is the largest market for chloroquine drugs for COVID-19, followed by Europe and Asia Pacific. The growth in these regions is attributed to the high prevalence of COVID-19 cases and government initiatives to provide access to effective treatment options. Asia Pacific is expected to witness the highest growth rate during the forecast period due to the increasing awareness of chloroquine's effectiveness and the growing population in developing countries.

Market Overview The SARS-CoV-2 vaccine Vero cell market is anticipated to witness significant growth over the forecast period (2025-2033) due to the ongoing COVID-19 pandemic and the need for effective vaccines. The market is driven by increasing government initiatives, public awareness, rising incidence of COVID-19 cases, and the availability of advanced vaccine technologies. The global market is estimated to reach a value of USD X million by 2033, growing at a CAGR of X% over the forecast period. Key Trends and Segments The SARS-CoV-2 vaccine Vero cell market is segmented by application (humans, animals), type (live attenuated vaccines, inactivated vaccines), and region (North America, Europe, Asia Pacific, South America, Middle East & Africa). The human segment is expected to hold a dominant share due to the widespread vaccination campaigns for individuals to prevent COVID-19 infection. Inactivated vaccines currently account for a significant share of the market but live attenuated vaccines are gaining traction due to their potential for single-dose immunization. Key players in the market include Sinopharm, Sinovac Biotech, BIBP, IMBCAMS, China, and WIBP. North America and Asia Pacific are expected to dominate the market due to a high incidence of COVID-19 cases and the presence of major vaccine manufacturers in these regions. SARS-CoV-2 Vaccine (Vero Cell) Market Overview The global SARS-CoV-2 Vaccine (Vero Cell) market size is projected to reach $X million by 2026, growing at a CAGR of X% from 2021 to 2026. The growth of the market is primarily driven by the increasing prevalence of COVID-19, the rising demand for effective vaccines, and the government initiatives to accelerate vaccination rates. Key market insights The SARS-CoV-2 Vaccine (Vero Cell) market is highly competitive, with several key players operating in the market. The major players include Sinopharm, Sinovac Biotech, BIBP, IMBCAMS, China, WIBP, and others. The market is segmented based on application, type, and region. The application segment includes adults and children. The type segment includes single-dose and multi-dose vaccines. Regionally, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is the largest market for SARS-CoV-2 Vaccine (Vero Cell) due to the high prevalence of COVID-19 in the region. The market in North America is also expected to grow significantly due to the increasing demand for effective vaccines.

COVID-19 Diagnostic Testing Market Outlook

The COVID-19 diagnostic testing market size was valued at USD 85 billion in 2023, with a forecasted value of USD 75 billion by 2032, growing at a CAGR of -1.3% during the forecast period. The market's decline is primarily driven by the decreasing number of COVID-19 cases and the widespread availability of vaccines. Despite the downward trend, the market is expected to maintain a significant presence due to ongoing testing requirements in various sectors, evolving virus variants, and the need for early detection in future outbreaks.

One of the main growth factors for the COVID-19 diagnostic testing market is the increasing awareness of the importance of early detection and prevention. Governments and health organizations worldwide have emphasized the necessity of mass testing to control the spread of the virus. Investments in healthcare infrastructure and the development of innovative testing methods have also played a crucial role in maintaining the market's momentum. Moreover, the emergence of new variants has underscored the need for continuous testing and monitoring, ensuring that the market remains relevant.

Technological advancements have significantly influenced the growth of the COVID-19 diagnostic testing market. The development of rapid and accurate testing methods, such as molecular and antigen tests, has revolutionized the industry. These technologies have enabled healthcare providers to quickly identify and isolate infected individuals, thereby preventing further transmission. Additionally, advancements in at-home testing kits have made it more convenient for individuals to monitor their health status, leading to increased adoption of these products.

The expanding applications of COVID-19 diagnostic testing beyond healthcare settings have also contributed to market growth. Many industries, including travel, hospitality, and education, have adopted regular testing protocols to ensure the safety of their employees and customers. This widespread adoption has created a sustained demand for diagnostic tests, even as the number of cases fluctuates. Furthermore, the integration of testing with digital health platforms and mobile applications has streamlined the process, making it easier for individuals to access and interpret their results.

Regionally, North America has been a significant market for COVID-19 diagnostic testing, driven by the high number of cases and robust healthcare infrastructure. Europe and Asia Pacific have also exhibited strong growth, supported by government initiatives and increasing awareness about the importance of testing. In contrast, regions like Latin America and the Middle East & Africa have faced challenges due to limited healthcare infrastructure and resources. However, international aid and collaborations have helped to mitigate some of these issues, fostering growth in these markets.

Test Type Analysis

The COVID-19 diagnostic testing market is segmented into molecular tests, antigen tests, and antibody tests. Molecular tests, such as RT-PCR, remain the gold standard due to their high accuracy and reliability. These tests detect the virus's genetic material and are widely used in hospital and laboratory settings. Despite their longer turnaround time, molecular tests are preferred for definitive diagnosis and for confirming cases of COVID-19, especially in symptomatic individuals and high-risk populations.

Antigen tests have gained popularity due to their rapid turnaround time and ease of use. These tests detect specific proteins on the surface of the virus and can provide results within minutes. While they are less accurate than molecular tests, antigen tests are valuable for mass screening and point-of-care testing. Their ability to quickly identify infected individuals makes them crucial in settings where immediate results are needed, such as airports, schools, and workplaces.

Antibody tests, also known as serology tests, detect the presence of antibodies in the blood, indicating a past infection. These tests play a crucial role in understanding the spread of the virus and the population's immunity levels. While not used for diagnosing active infections, antibody tests provide valuable data for epidemiological studies and vaccine efficacy assessments. They have been instrumental in guiding public health strategies and vaccination campaigns.

The implementation of a <a href="https://dataintelo.com/report/global-covid-19-health-code-market" target="_blank"

The increasing prevalence of COVID-19 and the subsequent rise in testing have fueled the demand for medical swabs, which are essential components of sample collection. The global medical swab for COVID-19 test market is anticipated to grow from a value of USD XX million in 2025 to USD XX million by 2033, with a CAGR of XX%. The market drivers include the increasing number of COVID-19 cases, the need for early detection and diagnosis, and government regulations mandating testing. The market for medical swabs for COVID-19 testing is segmented by application (hospitals, clinics, and diagnostic laboratories) and type (nasal swabs, oropharyngeal swabs, and combined nasopharyngeal/oropharyngeal swabs). The nasal swab segment accounted for the largest market share in 2025 due to its convenience and cost-effectiveness. Geographically, North America and Europe currently dominate the market due to the high incidence of COVID-19 and well-established healthcare systems. However, the Asia-Pacific region is expected to witness significant growth in the coming years due to the rising healthcare expenditure and increasing awareness of COVID-19 testing.

This is the dataset, trained model, and software companion for the paper titled: Characterizing Anti-Asian Rhetoric During The COVID-19 Pandemic: A Sentiment Analysis Case Study on Twitter accepted for the Workshop on Data for the Wellbeing of Most Vulnerable of the ICWSM 2022 conference.

The COVID-19 pandemic has shown a measurable increase in the usage of sinophobic comments or terms on online social media platforms. In the United States, Asian Americans have been primarily targeted by violence and hate speech stemming from negative sentiments about the origins of the novel SARS-CoV-2 virus. While most published research focuses on extracting these sentiments from social media data, it does not connect the specific news events during the pandemic with changes in negative sentiment on social media platforms. In this work we combine and enhance publicly available resources with our own manually annotated set of tweets to create machine learning classification models to characterize the sinophobic behavior. We then applied our classifier to a pre-filtered longitudinal dataset spanning two years of pandemic related tweets and overlay our findings with relevant news events.

This dataset presents an overview of platforms and registries that store, harmonize, and, in some cases, share COVID-19-related participant-level data, including clinical-epidemiological, human and pathogen OMICs, and high dimensional imaging data. The dataset provides an in-depth review of adherence to the FAIR principles, governance, benefit sharing and other ethical concerns related to resources that share harmonized, participant-level data for the research response to COVID-19. Systematic searches were conducted between April 2020 and June 2021 to identify relevant platforms and registries. We applied natural language processing to the CORD-19 dataset in March of 2021 and consulted with COVID-19 focused researchers in Asia, Africa, and Latin America to identify non-English language COVID-19-related data sharing resources.

Hydroxychloroquine Market Overview and Drivers: The global hydroxychloroquine market is projected to reach a value of USD 3.96 billion by 2033, exhibiting a remarkable CAGR of 26.90% during the forecast period. The increasing prevalence of rheumatoid arthritis and lupus erythematosus, coupled with the rising adoption of hydroxychloroquine for treating COVID-19, are major drivers of market growth. Additionally, the drug's effectiveness in preventing malaria in endemic regions contributes to its expanding market size. Moreover, ongoing clinical trials exploring hydroxychloroquine's potential in treating other autoimmune disorders, such as multiple sclerosis and Alzheimer's disease, present promising opportunities for future growth. Market Segmentation and Regional Insights: Based on application, the rheumatoid arthritis segment holds a dominant share, attributed to the high prevalence of this condition worldwide. The COVID-19 segment is expected to witness significant growth due to the widespread use of hydroxychloroquine as a potential treatment for the virus. Geographically, North America leads the market due to the high incidence of rheumatoid arthritis and COVID-19 cases, as well as well-established healthcare infrastructure. The Asia-Pacific region is projected to exhibit the highest growth rate, driven by increasing healthcare spending and a large population with a high prevalence of malaria. Leading manufacturers in the hydroxychloroquine market include Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Zydus Cadila, among others, who are leveraging strategic initiatives, such as product innovation and partnerships, to gain market share. Recent developments include: , June 2021:A prominent creator and producer of GMP-grade human induced pluripotent stem cells, RheinCell Therapeutics GmbH, will be acquired by Catalent, Inc., according to the company's announcement. The company's current stem cell therapy process development and production capabilities will benefit from this purchase., December 2020:In order to increase the manufacturing capacity for efficient production and manufacturing of voclosporin, Lonza stated that they have expanded their relationship with Aurinia Pharmaceuticals.. Key drivers for this market are: . Rise in the demand due to COVID-19 epidemic, . Favorable regulatory scenario. Potential restraints include: . XXX. Notable trends are: Surge in the spread of the COVID-19 globally is driving the market growth.

COVID-19 Rapid Diagnostic Test Market Outlook

The COVID-19 Rapid Diagnostic Test market size is projected to reach USD 15.7 billion by 2032, up from USD 6.2 billion in 2023, growing at a CAGR of 10.5% during the forecast period. The global market for rapid diagnostic tests has expanded significantly due to the urgent need for quick and efficient detection of COVID-19 to control and mitigate the pandemic's spread. This growth is driven by various factors including advancements in diagnostic technologies, increased healthcare spending, and the ongoing need for rapid and reliable testing solutions.

One key growth factor for this market is the pressing demand for widespread and frequent testing to monitor and control the spread of the virus. Governments and healthcare organizations across the globe have emphasized the importance of rapid testing as a critical component of public health strategies. This has resulted in significant investments in testing infrastructure and the rapid development and deployment of diagnostic tests. Additionally, the rise in COVID-19 cases in various regions continues to fuel the demand for rapid diagnostic tests, ensuring that the market remains robust.

Technological advancements in diagnostic methods have also played a crucial role in the growth of the COVID-19 Rapid Diagnostic Test market. Innovations such as Lateral Flow Assays, RT-PCR, and Isothermal Amplification have enhanced the speed, accuracy, and reliability of COVID-19 testing. These technologies have made it possible to conduct tests outside traditional laboratory settings, making them accessible to a broader population. The ability to deliver quick results has been particularly beneficial in controlling the spread of the virus in high-risk areas and settings.

Furthermore, the growing awareness among the general population regarding the importance of early detection and diagnosis has contributed to the market's expansion. With the ongoing threat of new variants and the possibility of future outbreaks, there is a heightened focus on maintaining testing capacities. Public health campaigns and educational initiatives have underscored the significance of regular testing, leading to increased adoption of rapid diagnostic tests among individuals and institutions alike.

From a regional perspective, North America has been a significant market for COVID-19 rapid diagnostic tests, driven by high healthcare expenditure, advanced healthcare infrastructure, and strong governmental support. Europe also represents a substantial market share, with several countries adopting widespread testing initiatives to manage their COVID-19 situations effectively. The Asia Pacific region is anticipated to witness the highest growth rate, owing to the large population base, increasing healthcare investments, and rising awareness about the importance of rapid diagnostics.

Product Type Analysis

The COVID-19 Rapid Diagnostic Test market is segmented by product types, including Antigen Tests, Antibody Tests, and Nucleic Acid Amplification Tests (NAATs). Each product type offers unique advantages and is utilized in different scenarios, contributing to the overall market growth. Antigen tests have gained widespread popularity due to their ability to deliver quick results, making them ideal for mass screening and point-of-care testing. These tests detect specific proteins from the virus and are highly effective in identifying active infections, particularly in symptomatic individuals.

Antibody tests, on the other hand, are used to determine if a person has been previously infected with the virus by detecting antibodies in their blood. These tests are essential for understanding the spread of the virus within a community and for epidemiological studies. Although they are not used for diagnosing active infections, they play a crucial role in seroprevalence studies and vaccine efficacy assessments. The demand for antibody tests has been driven by the need to monitor immune responses and track the development of herd immunity.

Nucleic Acid Amplification Tests (NAATs), including RT-PCR, are considered the gold standard for COVID-19 diagnosis due to their high sensitivity and specificity. These tests detect the viral RNA and are capable of identifying the virus even in the early stages of infection. Despite being more time-consuming and requiring specialized laboratory equipment, NAATs are widely used in hospitals and diagnostic centers for accurate and reliable diagnosis. The continued reliance on NAATs for definitive COVID-19 diagnosis ensures their significant sha